Skip to content

Artiva Biotherapeutics, Inc. ARTV Payments for finance leases

Payments for finance leases at other companies

Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$86K-74.8%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$13K

Other financials

Income statement

See full
Revenue-
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%
Free cash flow-$21.2M-4.1%

Valuation

See full
Market cap$429.03M+1,015%
Enterprise value$417.88M+1,832%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-67.9%
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeasePrincipalPayments.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s payments for finance leases.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s payments for finance leases?
Artiva Biotherapeutics, Inc. (ARTV) reported payments for finance leases of $33K in Q1 2026.
How has Artiva Biotherapeutics, Inc.'s payments for finance leases changed year-over-year?
Artiva Biotherapeutics, Inc.'s payments for finance leases decreased by 0.0% year-over-year, from $33K to $33K.
What does payments for finance leases mean?
Principal payments on finance lease obligations, reducing the lease liability on the balance sheet.